NR 603 CEA Final Exam Bundle –
Chamberlain University (2 Exam Sets)
Course: NR 603 – Advanced Clinical Diagnosis
(Clinical Evaluation & Assessment)
Institution: Chamberlain University
Focus: Final Exam and Comprehensive CEA
Content
Total Questions: 200+ (with Answer Key and
Detailed Rationales)
EXAM OVERVIEW
1
,The NR 603 CEA (Clinical Evaluation and
Assessment) Final Exam is a comprehensive
assessment for advanced practice nursing students at
Chamberlain University. The exam covers advanced
pathophysiology, pharmacotherapeutics, diagnostic
decision-making, and holistic patient management
across multiple body systems. Questions are
formatted as multiple-choice clinical scenarios
designed to mirror the actual exam and test clinical
reasoning skills.
SECTION 1: CARDIOVASCULAR SYSTEM
Questions 1-25
Question 1
2
,A patient presents with bradycardia, severe nausea,
and substernal pain. STEMI was identified on the
EKG. Which region of the heart is most likely
involved?
A) Lateral Wall
B) Anterior Wall
C) Inferior Wall
D) Posterior Wall
Correct Answer: C) Inferior Wall
Rationale: Inferior wall myocardial infarctions
(IWMI) are often associated with bradycardia and
nausea due to vagal stimulation and involvement of
the right coronary artery. The inferior leads (II, III,
aVF) show ST-segment elevation.
Question 2
3
, A patient with an EF of 28% following an MI should
be evaluated for which protective intervention?
A) Ordering a Holter monitor for 7 days post-
discharge
B) Ordering a new transthoracic echocardiogram and
order a Lifevest if EF is less than 35%
C) Dual anti-platelet therapy for 6 months
D) Increasing beta-blocker therapy only
Correct Answer: B) Ordering a new transthoracic
echocardiogram and order a Lifevest if EF is less
than 35%
Rationale: Patients with an EF less than 35% are at
increased risk of sudden cardiac death. A baseline
echo is needed at discharge to provide a baseline for
improvement vs their repeat echo in 2-3 months.
Most patients are not eligible for an AICD for 90
days, so a Lifevest provides temporary protection.
4
Chamberlain University (2 Exam Sets)
Course: NR 603 – Advanced Clinical Diagnosis
(Clinical Evaluation & Assessment)
Institution: Chamberlain University
Focus: Final Exam and Comprehensive CEA
Content
Total Questions: 200+ (with Answer Key and
Detailed Rationales)
EXAM OVERVIEW
1
,The NR 603 CEA (Clinical Evaluation and
Assessment) Final Exam is a comprehensive
assessment for advanced practice nursing students at
Chamberlain University. The exam covers advanced
pathophysiology, pharmacotherapeutics, diagnostic
decision-making, and holistic patient management
across multiple body systems. Questions are
formatted as multiple-choice clinical scenarios
designed to mirror the actual exam and test clinical
reasoning skills.
SECTION 1: CARDIOVASCULAR SYSTEM
Questions 1-25
Question 1
2
,A patient presents with bradycardia, severe nausea,
and substernal pain. STEMI was identified on the
EKG. Which region of the heart is most likely
involved?
A) Lateral Wall
B) Anterior Wall
C) Inferior Wall
D) Posterior Wall
Correct Answer: C) Inferior Wall
Rationale: Inferior wall myocardial infarctions
(IWMI) are often associated with bradycardia and
nausea due to vagal stimulation and involvement of
the right coronary artery. The inferior leads (II, III,
aVF) show ST-segment elevation.
Question 2
3
, A patient with an EF of 28% following an MI should
be evaluated for which protective intervention?
A) Ordering a Holter monitor for 7 days post-
discharge
B) Ordering a new transthoracic echocardiogram and
order a Lifevest if EF is less than 35%
C) Dual anti-platelet therapy for 6 months
D) Increasing beta-blocker therapy only
Correct Answer: B) Ordering a new transthoracic
echocardiogram and order a Lifevest if EF is less
than 35%
Rationale: Patients with an EF less than 35% are at
increased risk of sudden cardiac death. A baseline
echo is needed at discharge to provide a baseline for
improvement vs their repeat echo in 2-3 months.
Most patients are not eligible for an AICD for 90
days, so a Lifevest provides temporary protection.
4
